Linked Life Data

19364933

Source:http://linkedlifedata.com/resource/pubmed/id/19364933

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2009-4-14
pubmed:databankReference
pubmed:abstractText
Several questions arise concerning the use of the anti-CD25 antibody daclizumab to treat multiple sclerosis (MS).
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/19364933-10467383, http://linkedlifedata.com/resource/pubmed/commentcorrection/19364933-11420036, http://linkedlifedata.com/resource/pubmed/commentcorrection/19364933-15161974, http://linkedlifedata.com/resource/pubmed/commentcorrection/19364933-1545026, http://linkedlifedata.com/resource/pubmed/commentcorrection/19364933-15499632, http://linkedlifedata.com/resource/pubmed/commentcorrection/19364933-16301666, http://linkedlifedata.com/resource/pubmed/commentcorrection/19364933-16585503, http://linkedlifedata.com/resource/pubmed/commentcorrection/19364933-16596564, http://linkedlifedata.com/resource/pubmed/commentcorrection/19364933-17603762, http://linkedlifedata.com/resource/pubmed/commentcorrection/19364933-17709711, http://linkedlifedata.com/resource/pubmed/commentcorrection/19364933-17904646, http://linkedlifedata.com/resource/pubmed/commentcorrection/19364933-18567923, http://linkedlifedata.com/resource/pubmed/commentcorrection/19364933-18808743, http://linkedlifedata.com/resource/pubmed/commentcorrection/19364933-6685237, http://linkedlifedata.com/resource/pubmed/commentcorrection/19364933-8926489
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1538-3687
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
66
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
483-9
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:19364933-Adult, pubmed-meshheading:19364933-Antibodies, Monoclonal, pubmed-meshheading:19364933-Antibodies, Monoclonal, Humanized, pubmed-meshheading:19364933-Brain, pubmed-meshheading:19364933-CD4-Positive T-Lymphocytes, pubmed-meshheading:19364933-CD8-Positive T-Lymphocytes, pubmed-meshheading:19364933-Disability Evaluation, pubmed-meshheading:19364933-Dose-Response Relationship, Drug, pubmed-meshheading:19364933-Drug Administration Schedule, pubmed-meshheading:19364933-Drug Therapy, Combination, pubmed-meshheading:19364933-Female, pubmed-meshheading:19364933-Humans, pubmed-meshheading:19364933-Immunoglobulin G, pubmed-meshheading:19364933-Immunosuppressive Agents, pubmed-meshheading:19364933-Infusions, Intravenous, pubmed-meshheading:19364933-Interferon-beta, pubmed-meshheading:19364933-Interleukin-2 Receptor alpha Subunit, pubmed-meshheading:19364933-Killer Cells, Natural, pubmed-meshheading:19364933-Magnetic Resonance Imaging, pubmed-meshheading:19364933-Male, pubmed-meshheading:19364933-Middle Aged, pubmed-meshheading:19364933-Multiple Sclerosis, pubmed-meshheading:19364933-Treatment Outcome, pubmed-meshheading:19364933-Young Adult
pubmed:year
2009
pubmed:articleTitle
Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.
pubmed:affiliation
Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bldg 10, Room 5C103, 10 Center Dr, MSC 1400, Bethesda, MD 20892, USA. Bibi.Bielekova@nih.gov
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Clinical Trial, Phase II, Research Support, N.I.H., Intramural